Amarin reported $449.41M in Equity Capital and Reserves for its fiscal quarter ending in March of 2026.





Equity Capital And Reserves Change Date
AbbVie USD -6.66B 3.39B Mar/2026
Alnylam Pharmaceuticals USD 1.08B 286.2M Mar/2026
Amarin USD 449.41M 9.87M Mar/2026
AstraZeneca USD 47.33B 1.33B Mar/2026
BioCryst Pharmaceuticals USD -553.84M 434.69M Mar/2026
DBV Technologies USD 168.77M 115.92M Dec/2025
Esperion Therapeutics USD -307.93M 5.97M Mar/2026
GlaxoSmithKline GBP 17.42B 1.05B Mar/2026
Halozyme Therapeutics USD 219.64M 170.82M Mar/2026
Heron Therapeutics USD 9.14M 4.15M Mar/2026
Ionis Pharmaceuticals USD 491.41M 2.32M Mar/2026
Nektar Therapeutics USD 89.83M 4.75M Dec/2025
Neurocrine Biosciences USD 3.41B 154.3M Mar/2026
Novartis USD 38.93B 7.2B Mar/2026